Literature DB >> 29228771

Curcumin Derivative Epigenetically Reactivates Nrf2 Antioxidative Stress Signaling in Mouse Prostate Cancer TRAMP C1 Cells.

Wenji Li, Zheng-Yuan Su1, Yue Guo, Chengyue Zhang, Renyi Wu, Linbo Gao, Xi Zheng, Zhi-Yun Du, Kun Zhang, Ah-Ng Kong.   

Abstract

The carcinogenesis of prostate cancer (PCa) in TRAMP model is highly correlated with hypermethylation in the promoter region of Nrf2 and the accompanying reduced transcription of Nrf2 and its regulated detoxifying genes. We aimed to investigate the effects of (3E,5E)-3,5-bis-(3,4,5-trimethoxybenzylidene)-tetrahydro-thiopyran-4-one (F10) and (3E,5E)-3,5-bis-(3,4,5-trimethoxy-benzylidene)-tetrahydropyran-4-one (E10), two synthetic curcumin derivatives, on restoring Nrf2 activity in TRAMP C1 cells. HepG2-C8 cells transfected with an antioxidant-response element (ARE)-luciferase vector were treated with F10, E10, curcumin, and sulforaphane (SFN) to compare their effects on Nrf2-ARE pathways. We performed real-time quantitative PCR and Western blotting to investigate the effects of F10 and E10 on Nrf2, correlated phase II detoxification genes. We also measured expression and activity of DNMTand HDAC enzymes. Enrichment of H3K27me3 on the promoter region of Nrf2 was explored with a chromatin immunoprecipitation (ChIP) assay. Methylation of the CpG region in Nrf2 promoter was doubly examined by bisulfite genomic sequencing (BGS) and methylation DNA immunoprecipitation (MeDIP). Compared with curcumin and SFN, F10 is more potent in activating Nrf2-ARE pathways. Both F10 and E10 enhanced level of Nrf2 and the correlated phase II detoxifying genes. BGS and MeDIP assays indicated that F10 but not E10 hypomethylated the Nrf2 promoter. F10 also downregulated the protein level of DNMT1, DNMT3a, DNMT3b, HDAC1, HDAC4, and HDAC7 and the activity of DNMTs and HDACs. F10 but not E10 effectively reduced the accumulation of H3k27me3 on the promoter of Nrf2. F10 and E10 can activate the Nrf2-ARE pathway and increase the level of Nrf2 and correlated phase II detoxification genes. The reactivation effect on Nrf2 by F10 in TRAMP C1 may come from demethylation, decrease of HDACs, and inhibition of H3k27me3 accumulation.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29228771      PMCID: PMC6295337          DOI: 10.1021/acs.chemrestox.7b00248

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  33 in total

Review 1.  Epigenetics in cancer.

Authors:  Manel Esteller
Journal:  N Engl J Med       Date:  2008-03-13       Impact factor: 91.245

2.  CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer.

Authors:  Jörg Ellinger; Patrick J Bastian; Thomas Jurgan; Katharina Biermann; Philip Kahl; Lukas C Heukamp; Nicolas Wernert; Stefan C Müller; Alexander von Ruecker
Journal:  Urology       Date:  2008-01       Impact factor: 2.649

3.  Curcumin analogues with high activity for inhibiting human prostate cancer cell growth and androgen receptor activation.

Authors:  Dai-Ying Zhou; Ning Ding; Zhi-Yun Du; Xiao-Xing Cui; Hong Wang; Xing-Chuan Wei; Allan H Conney; Kun Zhang; Xi Zheng
Journal:  Mol Med Rep       Date:  2014-07-14       Impact factor: 2.952

4.  Sulforaphane enhances Nrf2 expression in prostate cancer TRAMP C1 cells through epigenetic regulation.

Authors:  Chengyue Zhang; Zheng-Yuan Su; Tin Oo Khor; Limin Shu; Ah-Ng Tony Kong
Journal:  Biochem Pharmacol       Date:  2013-02-14       Impact factor: 5.858

5.  Dietary Phytochemicals and Cancer Chemoprevention: A Perspective on Oxidative Stress, Inflammation, and Epigenetics.

Authors:  Wenji Li; Yue Guo; Chengyue Zhang; Renyi Wu; Anne Yuqing Yang; John Gaspar; Ah-Ng Tony Kong
Journal:  Chem Res Toxicol       Date:  2016-12-05       Impact factor: 3.739

6.  Trends in prostate cancer in the United States.

Authors:  Otis W Brawley
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

7.  DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases.

Authors:  Martin J Aryee; Wennuan Liu; Julia C Engelmann; Philipp Nuhn; Meltem Gurel; Michael C Haffner; David Esopi; Rafael A Irizarry; Robert H Getzenberg; William G Nelson; Jun Luo; Jianfeng Xu; William B Isaacs; G Steven Bova; Srinivasan Yegnasubramanian
Journal:  Sci Transl Med       Date:  2013-01-23       Impact factor: 17.956

8.  Aberrant DNA methylation and prostate cancer.

Authors:  Sunipa Majumdar; Eric Buckles; John Estrada; Shahriar Koochekpour
Journal:  Curr Genomics       Date:  2011-11       Impact factor: 2.236

9.  Inhibition of PI3K/AKT/mTOR axis disrupts oxidative stress-mediated survival of melanoma cells.

Authors:  Heather G Hambright; Peng Meng; Addanki P Kumar; Rita Ghosh
Journal:  Oncotarget       Date:  2015-03-30

10.  High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer.

Authors:  Siri H Strand; Soren Hoyer; Anne-Sofie Lynnerup; Christa Haldrup; Tine Maj Storebjerg; Michael Borre; Torben F Orntoft; Karina D Sorensen
Journal:  Clin Epigenetics       Date:  2015-10-15       Impact factor: 6.551

View more
  11 in total

1.  Pharmacokinetics and pharmacodynamics of three oral formulations of curcumin in rats.

Authors:  Lujing Wang; Wenji Li; David Cheng; Yue Guo; Renyi Wu; Ran Yin; Shanyi Li; Hsiao-Chen Kuo; Rasika Hudlikar; Hilly Yang; Brian Buckley; Ah-Ng Kong
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-02-04       Impact factor: 2.745

2.  The role of natural products in revealing NRF2 function.

Authors:  Donna D Zhang; Eli Chapman
Journal:  Nat Prod Rep       Date:  2020-05-13       Impact factor: 13.423

3.  The dietary flavone luteolin epigenetically activates the Nrf2 pathway and blocks cell transformation in human colorectal cancer HCT116 cells.

Authors:  Qian Zuo; Renyi Wu; Xi Xiao; Caizhi Yang; Yuqing Yang; Chao Wang; Lizhu Lin; Ah-Ng Kong
Journal:  J Cell Biochem       Date:  2018-08-20       Impact factor: 4.429

Review 4.  Epigenetic Therapeutics Targeting NRF2/KEAP1 Signaling in Cancer Oxidative Stress.

Authors:  Shunhao Zhang; Sining Duan; Zhuojun Xie; Wanlin Bao; Bo Xu; Wenbin Yang; Lingyun Zhou
Journal:  Front Pharmacol       Date:  2022-06-09       Impact factor: 5.988

Review 5.  Oxidative stress and redox signaling in CRPC progression: therapeutic potential of clinically-tested Nrf2-activators.

Authors:  Debasis Mondal; Devin Narwani; Shahnawaz Notta; Dawood Ghaffar; Nikhil Mardhekar; Syed S A Quadri
Journal:  Cancer Drug Resist       Date:  2021-03-19

Review 6.  The double-edged roles of ROS in cancer prevention and therapy.

Authors:  Yawei Wang; Huan Qi; Yu Liu; Chao Duan; Xiaolong Liu; Tian Xia; Di Chen; Hai-Long Piao; Hong-Xu Liu
Journal:  Theranostics       Date:  2021-03-04       Impact factor: 11.556

Review 7.  Anti-Viral Potential and Modulation of Nrf2 by Curcumin: Pharmacological Implications.

Authors:  Mahdie Rahban; Mehran Habibi-Rezaei; Mansoureh Mazaheri; Luciano Saso; Ali A Moosavi-Movahedi
Journal:  Antioxidants (Basel)       Date:  2020-12-04

Review 8.  Phytochemicals in Inhibition of Prostate Cancer: Evidence from Molecular Mechanisms Studies.

Authors:  Qiongyu Hao; Yanyuan Wu; Jaydutt V Vadgama; Piwen Wang
Journal:  Biomolecules       Date:  2022-09-16

Review 9.  Targeting Crosstalk between Nrf-2, NF-κB and Androgen Receptor Signaling in Prostate Cancer.

Authors:  Namrata Khurana; Suresh C Sikka
Journal:  Cancers (Basel)       Date:  2018-09-25       Impact factor: 6.639

Review 10.  Plant Bioactives and the Prevention of Prostate Cancer: Evidence from Human Studies.

Authors:  Tracey L Livingstone; Gemma Beasy; Robert D Mills; Jenny Plumb; Paul W Needs; Richard Mithen; Maria H Traka
Journal:  Nutrients       Date:  2019-09-18       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.